Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
about
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaSulpiride augmentation for schizophreniaSulpiride augmentation for schizophreniaPrevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaDevelopment of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future ApplicationsA translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyImprovement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling.Cost of antipsychotic polypharmacy in the treatment of schizophrenia.Medication adherence levels and differential use of mental-health services in the treatment of schizophreniaTreatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patientsRelapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.Antipsychotic polypharmacy in a regional health service: a population-based study.Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapyAntipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviorTreatment resistant schizophrenia: a comprehensive survey of randomised controlled trials.Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.Validation of a claims-based antipsychotic polypharmacy measureThe 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entryThe burden of depressive symptoms in the long-term treatment of patients with schizophrenia.Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysisPrevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia.Antipsychotics prescribing patterns of patients with schizophrenia admitted to korean general hospital psychiatric unit: 2001 to 2008.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practicePredictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in MalaysiaAdherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional AnalysisDo doctors agree on doses of antipsychotic medications?Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysisAntipsychotic polypharmacy in schizophrenia: benefits and risks.Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.Comparison of treatment patterns in schizophrenia between China and Japan (2001-2009).Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports.
P2860
Q21260279-D1E7DF6A-AEED-47C5-A463-1ED066D98CFAQ24240818-3F04391D-E79A-4DDF-B53B-6CA3BDF5003EQ24241371-B0D40101-E53A-4301-A833-69E36C64F591Q27028197-5857A45F-18F3-4295-A70F-877834534FFBQ28248687-4E0F4C96-8C64-4100-A9B6-74352650BDCEQ28552825-A55AB307-5A82-42EC-B1E5-A47CB1C2ECB4Q30485065-BD88C45E-81C6-4DBE-8DE4-953204CB574CQ33284145-C441A70E-EB43-46E4-806E-123A9901914EQ33327172-769EC504-7CA4-47A0-9FF5-0594449EED09Q33399275-AC088ACE-8A0D-4701-9E2F-053DFC06310DQ33488323-BA5848C7-FA13-4268-B053-1688882297A1Q33818732-03BE6642-F849-433C-9943-688B8FE5F40CQ34269517-EE549202-C3CD-4248-A9DA-9343B4AB4008Q34603527-6955745A-2B43-4C45-A842-5E88E966518AQ34686544-4C12C05E-95E9-4DEB-9A5C-1CCF2551D508Q35175610-E3C7522C-B54C-4EF7-9B61-2C165C2B68D9Q35256929-674330B1-C917-466A-B7A3-A605EFBB37B5Q35608522-5830975E-F3E7-428A-9A6C-25F180F005F0Q35801221-6C03DB67-64EE-47B8-94A3-C75E5E40C127Q35851083-132DD59B-30E6-4D13-87BB-B443F443A4E1Q35921541-216A1918-37DC-417C-B66D-BA09BB3C73ACQ36024341-65EE14EA-781C-449B-8567-7F368042EDFFQ36057820-483F812D-0B93-49D7-80B0-1F15D07C909AQ36065092-5B6AFD45-8C45-49C5-8D96-746D8DCFD22CQ36556487-FD6716EE-28EF-4D8D-8B03-475C6CDF8FAEQ36599207-E72CE038-5EFC-4FBE-B1BF-8BF799BD9A33Q37029622-92070BF6-ECCA-4AA4-AA24-66D13A07FE2AQ37042072-62DB8AC9-4B69-4D4D-B728-44776FCCA04CQ37137001-7F82740D-8C7A-4D8E-BD80-9F4A81E08328Q37216848-5092B8B2-F3C0-45EE-B3E0-A4ACE4A0D466Q37281587-D5D2A0F1-650A-4EB9-AF47-08F305E6059EQ37294192-6E588525-7009-4DCC-8C8D-27A60729C7D4Q37405519-ACF295FC-A336-4D67-B7FC-D3862E7650EBQ37452761-9266A7AB-0C94-4534-AE37-96257E6DFF3EQ37514630-3CC4AF13-D60F-4B88-A88C-05F05D1FE590Q37609168-AB7E6355-8D70-4060-9489-1207338F6E70Q37863093-F014C973-90CA-4472-B7B0-135E8E86600AQ38769838-5852F835-9619-47DF-B866-BA9160E83A83Q38950803-E7BE5F2B-C7AE-421E-BB03-F7BA9465A722Q40050322-0B5BAADB-F77B-4B74-958E-22C4E66C559C
P2860
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@ast
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@en
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@nl
type
label
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@ast
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@en
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@nl
prefLabel
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@ast
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@en
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@nl
P2093
P2860
P3181
P356
P1433
P1476
Antipsychotic monotherapy and ...... a with atypical antipsychotics
@en
P2093
Baojin Zhu
Christoph Correll
Douglas Faries
P2860
P2888
P3181
P356
10.1186/1471-244X-5-26
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1042409635